대장내시경 검사기기 시장 : 구성 요소별, 검사 유형별, 사용성별, 치료 영역별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Colonoscopy Device Market is projected to grow by USD 4.11 billion at a CAGR of 8.07% by 2032.

The colonoscopy device market is being shaped by the global burden of colorectal cancer, the expansion of screening eligibility, and continued investment in high-definition endoscopy platforms, therapeutic accessories, and computer-aided detection. According to the International Agency for Research on Cancer, colorectal cancer accounted for more than 1.9 million new cases and more than 900,000 deaths worldwide in 2022, making early detection a central public health priority.

Demand is supported by guideline-driven screening, including the U.S. Preventive Services Task Force recommendation for adults aged 45 to 75 years, as well as rising adoption of minimally invasive diagnosis and treatment. Colonoscopy remains clinically important because it enables direct visualization, biopsy, polypectomy, hemostasis, and surveillance in a single procedure, positioning colonoscopy devices as essential assets for hospitals, ambulatory surgery centers, and specialty gastroenterology clinics.

Transformative Shifts in the Colonoscopy Device Landscape

The landscape is shifting from conventional visualization toward integrated, data-enabled endoscopy ecosystems. High-definition imaging, narrow-band and image-enhanced endoscopy, variable-stiffness scopes, improved insufflation, water-assisted techniques, and advanced resection accessories are helping clinicians detect subtle lesions while improving procedural efficiency and patient comfort.

At the same time, health systems are balancing higher screening volumes with workforce constraints, infection prevention requirements, and pressure to reduce procedure backlogs. These forces are accelerating interest in automated documentation, single-use components in selected settings, ergonomic device designs, and capital equipment models that support uptime, serviceability, reprocessing compliance, and interoperability with hospital information systems.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a meaningful performance layer in colonoscopy devices, particularly through computer-aided detection systems that flag suspected polyps in real time. Peer-reviewed randomized trials and meta-analyses have reported that AI-assisted colonoscopy can improve adenoma detection rates, a key quality indicator associated with reduced interval colorectal cancer risk.

The impact is cumulative rather than isolated: AI can support lesion detection, procedure quality measurement, documentation, training, and workflow analytics. The U.S. FDA authorization of the first AI-based colonoscopy detection aid in 2021 illustrates the regulatory pathway for clinical deployment. However, adoption depends on validation across diverse populations, cybersecurity safeguards, clinician oversight, transparent performance monitoring, and integration with existing endoscopy towers and electronic health records.

Key Regional Insights

Asia-Pacific is gaining strategic importance due to population scale, aging demographics, expanding private healthcare, and rising colorectal cancer awareness in China, Japan, India, South Korea, and Australia. Japan and South Korea benefit from advanced endoscopy expertise, established hospital infrastructure, and organized screening practices, while China and India offer significant long-term demand as diagnostic capacity, specialty training, and tertiary care infrastructure expand across urban and regional healthcare systems.

North America remains a mature, innovation-led region supported by screening guidelines, reimbursement pathways, ambulatory endoscopy networks, and early adoption of AI-assisted colonoscopy. Europe benefits from structured screening programs, robust quality indicators, and strong regulatory emphasis on patient safety under medical device compliance frameworks. Latin America shows increasing demand as Brazil, Mexico, and other national systems expand gastroenterology access, although reimbursement variability and uneven specialist distribution affect adoption. The Middle East is supported by investments in advanced hospitals, specialist care, and digital health infrastructure, particularly in high-income health systems, while Africa is an emerging access-driven region where affordability, trained workforce availability, endoscopy unit density, and reprocessing infrastructure remain central adoption considerations.

Key Group Insights

ASEAN markets are gaining relevance as governments and private providers expand endoscopy capacity, particularly in urban centers with growing medical tourism, middle-class healthcare demand, and investments in tertiary hospitals. The GCC is investing in advanced hospital infrastructure, cancer prevention strategies, and specialist services, supporting adoption of premium colonoscopy systems, image-enhanced endoscopy, and digital endoscopy platforms.

The European Union is shaped by harmonized medical device regulation, structured colorectal cancer screening, screening quality standards, and value-based procurement. BRICS countries represent a large-volume opportunity because of population size, rising noncommunicable disease burden, increasing cancer awareness, and expanding healthcare expenditure, though purchasing patterns vary widely by public funding, local manufacturing policy, and hospital infrastructure. G7 markets lead in technology adoption, clinical guideline implementation, reimbursement maturity, and AI evaluation, while NATO countries overlap significantly with advanced Western healthcare systems where resilience, supply security, cybersecurity, and regulatory compliance are strategic procurement considerations for colonoscopy device deployment.

Key Country Insights

The United States is a leading country for colonoscopy devices due to strong screening recommendations, high procedure volumes, ambulatory surgery center penetration, payer coverage for preventive screening, and rapid evaluation of AI-enabled endoscopy. Canada benefits from provincial colorectal cancer screening programs and standardized quality initiatives, while Mexico and Brazil are expanding access through public and private healthcare investment, with demand concentrated in major urban centers and referral hospitals. In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain significant demand through national or regional screening initiatives, established gastroenterology networks, and quality-focused endoscopy services, while Russia presents opportunities shaped by hospital procurement needs and constrained by geopolitical, supply chain, and regulatory complexity.

China and India offer major long-term potential as healthcare systems scale diagnostic capacity, address rising colorectal cancer incidence, and expand specialist training and endoscopy infrastructure. Japan remains highly sophisticated in endoscopic imaging, early lesion detection, and therapeutic endoscopy, while South Korea combines strong screening participation with advanced hospital infrastructure and high technology readiness. Australia continues to benefit from organized bowel cancer screening, public health awareness, and high clinical standards, supporting demand for quality colonoscopy devices, reprocessing systems, and diagnostic and therapeutic accessories.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated innovation that improves adenoma detection, procedure efficiency, infection control, reprocessing reliability, and total cost of ownership. Product strategies should combine high-definition visualization, AI-enabled detection, ergonomic scope design, reliable reprocessing compatibility, durable service models, and accessory portfolios that support both diagnostic and therapeutic colonoscopy.

Commercial execution should be tailored by market maturity: emphasize reimbursement evidence, clinical workflow integration, and quality metrics in North America and Europe; capacity building, training, and distribution reach in Asia-Pacific and Latin America; and infrastructure partnerships in the Middle East and Africa. Organizations should also strengthen post-market surveillance, clinician education, cybersecurity controls, supply chain resilience, and regulatory readiness under frameworks such as FDA requirements and the EU Medical Device Regulation.

Research Methodology

This executive summary is based on a structured review of verified secondary sources, including global cancer statistics from the International Agency for Research on Cancer, screening guidance from national public health authorities, regulatory information from agencies such as the U.S. FDA, and peer-reviewed clinical literature on AI-assisted colonoscopy, adenoma detection, colorectal cancer screening, and endoscopy quality indicators.

The analysis evaluates demand drivers, technology trends, regional healthcare infrastructure, guideline adoption, regulatory context, reimbursement dynamics, clinical workflow needs, and device adoption patterns. Insights are synthesized using triangulation across clinical evidence, public health data, regulatory sources, payer considerations, and healthcare delivery indicators to support decision-making for manufacturers, investors, distributors, and healthcare providers without relying on market sizing, market share, or forecasting assumptions.

Conclusion

The colonoscopy device market is positioned for sustained relevance as healthcare systems intensify colorectal cancer prevention, expand screening access, and modernize endoscopy suites. Devices that improve visualization, detection accuracy, therapeutic capability, workflow efficiency, reprocessing safety, and patient outcomes are likely to command strategic value across both mature and emerging healthcare markets.

Artificial intelligence, advanced imaging, and integrated digital platforms will increasingly define competitive differentiation in colonoscopy devices. Market participants that align innovation with clinical evidence, regulatory compliance, service reliability, cybersecurity, clinician training, and regional access needs will be best positioned to support long-term growth and improved colorectal cancer prevention worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Colonoscopy Device Market, by Component

• 7.1. Colonoscope Devices
  • 7.1.1. Fiber-optic Colonoscopes
  • 7.1.2. Video Colonoscopes
• 7.2. Colonoscopy Accessories
• 7.3. Visualization Systems

8. Colonoscopy Device Market, by Procedure Type

• 8.1. Screening Colonoscopy
• 8.2. Diagnostic Colonoscopy
• 8.3. Surveillance Colonoscopy
• 8.4. Therapeutic Colonoscopy

9. Colonoscopy Device Market, by Usability

• 9.1. Reusable Systems
• 9.2. Single-Use Systems

10. Colonoscopy Device Market, by Therapeutic Area

• 10.1. Colorectal Cancer
• 10.2. Crohn's Disease
• 10.3. Lynch Syndrome
• 10.4. Ulcerative Colitis

11. Colonoscopy Device Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Clinics
• 11.3. Diagnostic Centers
• 11.4. Hospitals
• 11.5. Research Laboratories

12. Colonoscopy Device Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Colonoscopy Device Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Colonoscopy Device Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Ambu A/S
• 16.2. Avantis Medical Systems
• 16.3. Boston Scientific Corporation
• 16.4. Canon Medical Systems Corporation
• 16.5. ColoWrap, LLC.
• 16.6. ConMed Corporation
• 16.7. Dantschke Medizintechnik GmbH & Co. KG
• 16.8. Endomed Systems GmbH
• 16.9. FUJIFILM Holdings Corporation
• 16.10. G.I. View Ltd
• 16.11. Getinge AB
• 16.12. Hologic, Inc.
• 16.13. HOYA Corporation
• 16.14. Huger Medical Instrument Co.,Ltd
• 16.15. Karl Storz SE & Co. KG
• 16.16. Medtronic PLC
• 16.17. Olympus Corp.
• 16.18. Ottomed Endoscopy by Mitra Medical Services LLP
• 16.19. Pro Scope Systems LLC
• 16.20. Richard Wolf GmbH
• 16.21. SHAILI ENDOSCOPY PRIVATE LIMITED
• 16.22. Shanghai Shiyin Photoelectric Instrument Co.,Ltd.
• 16.23. Smith & Nephew Plc
• 16.24. Sonoscape Medical Corp
• 16.25. Steris Corporation
• 16.26. Stryker Corporation